Gilead Sciences (GILD) Releases Earnings Results

Gilead Sciences (NASDAQ:GILD) released its quarterly earnings data on Monday. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11, Bloomberg Earnings reports. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the company earned $2.70 earnings per share. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year.

Gilead Sciences (GILD) traded up $2.01 during trading hours on Tuesday, reaching $80.38. 13,166,852 shares of the company traded hands, compared to its average volume of 8,610,000. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market capitalization of $104,970.00, a price-to-earnings ratio of 9.14, a P/E/G ratio of -1.80 and a beta of 1.22.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s payout ratio is presently 23.66%.

GILD has been the topic of a number of analyst reports. William Blair restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Mizuho boosted their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $73.67 to $94.00 in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $85.58.

In related news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 578,333 shares of company stock worth $44,100,508 in the last three months. 1.30% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. Rowland & Co. Investment Counsel ADV bought a new stake in Gilead Sciences during the second quarter worth about $153,000. Kingfisher Capital LLC bought a new stake in Gilead Sciences during the second quarter worth about $212,000. Keel Point LLC boosted its stake in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 12 shares in the last quarter. Colony Group LLC bought a new stake in Gilead Sciences during the second quarter worth about $229,000. Finally, Linscomb & Williams Inc. boosted its stake in Gilead Sciences by 10.1% during the second quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock worth $411,000 after acquiring an additional 531 shares in the last quarter. 75.84% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Releases Earnings Results” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/06/gilead-sciences-gild-releases-earnings-results.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply